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THE effect of vaccination with diphtheria toxoid
(AD-M) on TNF and IL-6 production has been
studied in humans. In the present study it was
demonstrated that immunization with AD-M re-
sulted in changes of in vitro TNF and IL-6 produc-
tion by peripheral blood mononuclear cells. TNF
release was suppressed but IL-6 production was
stimulated. On the other hand, serum levels of
TNF were markedly increased over a period of 3
weeks. It was also demonstrated that the post-
vaccinal cytokine production disturbances may
be corrected by pretreatment with a new syn-
thetic hexapeptid (Imunofan(R)). It is possible that
the imunofan treatment could prevent some post-
vaccinal complications.
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Introduction
The safety of vaccination in the first instance
depends on the vaccine’s characteristics. It is
well known, however, that the vaccine’s appli-
cation always switches on a cascade of events
which results in cytokine release. Thus, the
spontaneous production of high levels of IL-4
and TNF-z after measles virus vaccination has
been shown. The transient increase of IL-6 in
serum has been also demonstrated after vaccina-
tion with brucella antigenic extracts and live,
attenuated Francisella tularensis in mice and
humans.2’3 Murine spleen cells taken at intervals
after infection and cultured with brucella anti-
gens produced elevated levels of IL-1, IL-6 and
TNF-z2. These cytokines play an important role
in the development of inflammation.4 The
inflammatory reactions, which are safe for
healthy individuals, may entail serious conse-
quences in children with a variety of forms of
immune disturbance. Production of at least one
of the aforesaid proinflammatory cytokines may
be regulated with a new immunomodulating
agent thymohexin (Imunofan(R)). This synthetic
hexapeptid is a modified analogue of the
thymopoietin II active centre.5 The inhibitory
effect of imunofan (IF) on TNF-ct production in
septic patients has been shown.6
In the present study, we investigated TNF and
IL-6 production after diphtheria toxoid vaccina-
tion and the possibility of cytokine level mod-
ulation by IF pretreatment.
Material and Methods
Subjects
Seventeen healthy adult volunteers (male and
female; mean age 30.4 years, range 22-54
years) were selected on the basis of at least a
1O-year period without revaccination.
Vaccine
Absorbed diphtheria toxoid with low content
(10 LF/ml) of antigens (AD-M) was obtained
from BIOMED (Petrovo-Dal’neie, Russia).
Immunomodulating hexapeptid
Imunofan (arginyl--aspartyl-lysyl-valyl-tyrosyl-
arginine) synthetic modified analogue of thymo-
poietin II active centre was obtained from
Bionox-Bios (Moscow, Russia).
Vaccination
All volunteers were divided into three groups.
The volunteers of the first group (five subjects)
received 0.5 ml AD-M; the individuals of the
second and third group (six subjects in each)
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received AD-M and 1 ml (0.05 mg) IF or IF only.
Both AD-M and IF were mixed in the same
syringe and injected subcutaneously within the
shoulder-blade region.
Blood collection
Blood was collected in heparin (25 IU/ml) and
in dry tubes (for serum collection) before
immunization and 1, 7, 14, 30 and 120 days
after immunization.
Cells and cultures
Peripheral blood mononuclear cells (PBMNCs)
were isolated from heparinized peripheral blood
by Ficoll-Verographin gradient sedimentation.
The cells were washed twice and resuspended
in RPMI-1640 medium (ICN, UK) supplemented
with 10% heat inactivated donor horse serum,
2 10-3 M HEPES, 2 mM L-glutamine, 2.8
10-6 M 2-mercaptoethanol, and 20 ktg/ml genta-
mycin. Cells (106 cells/ml) were cultivated for 2
or 14 h at 37C in a humidified atmosphere
containing 5% CO2 in the wells (1.5 ml per
well) of 24-well plates (Nunc, Denmark). The
supernatants were collected and stored at
-20C until cytokine activity examination.
IL-6 activity assay
IL-6 activity was determined using IL-6-depen-
dent hybridoma cell line D6C8.
8 Briefly, serial
dilutions of culture supernatants and recombi-
nant IL-6 (code 89/45, NIBSC, UK) as a
standard, were incubated in 96-well microplates
with cells (5 104 cells/welD, in a total volume
of 200 # at 37C. The cells were cultivated for
48 h in RPMI-1640 medium supplemented with
5% human dialysed AB-serum. Four hours before
the end of cultivation the cells were pulsed
with 40 kBq per well of [3H]-thymidine, har-
vested with a cell harvester and counted by
using a liquid scintillation counter.
Antitoxic antibody assay
Indirect haemagglutination with diphtheria tox-
oid attached to erythrocytes has been per-
formed. Antitoxic antibody titre were deter-
mined using a commercial kit obtained from
BIOMED (Petrovo-Dal’neie, Russia).
Statistical analysis
Statistical comparison were performed using
the Wilcoxon-Mann-Whitney’s U criterion,
Student’s t-test, and Fisher’s exact test.
TNF activity assay
TNF activity was determined by the method of
Ruff and Gifford7 with some modifications.
Briefly, L929 cells were seeded at a density
3 104 cells per well in 96-well plates in
lO01al of medium 199 to which 10% heat
inactivated calf bovine serum and gentamycin
had been added. Plates were incubated at 37C
in a humidified atmosphere containing 5% CO2
until the monolayer formation. After the culture
medium elimination, two-fold serial dilution of
the samples (100 tal of each dilution) and 100 txl
fresh culture medium with 2 g/ml of actinomy-
cin D (Serva, Germany) were added, and further
incubated for 18 h at the same conditions.
Supernatants were then removed and cells
stained with 0.2% crystal violet (Sigma, USA).
After washing and drying plates were finally
read at 540 nm on a Titertek Multiskan micro-
Elisa reader. Human recombinant TNF (Institute
of Bioorganic Chemistry, Moscow, Russia) was
used as internal standard. For the comparison of
an experimental and calibrating curves probit-
analysis method was used. TNF content in the
samples was expressed in pg/ml.
,Results
Changes in TNF production
As a rule LPS treatment stimulated TNF produc-
tion compared with untreated cultures but in
some cases such stimulation was not observed.
There was also donor-to-donor variability in the
levels of cytokine production before vaccination
(Table 1). In view of this fact our experimental
data was presented as a percentage of control.
AD-M (with or without IF) strongly sup-
pressed spontaneous and LPS-induced TNF pro-
duction by PBMNCs at the 7th day after
injections. The suppression was maintained at
the 14th day in subjects injected with AD-M
only, but those who received the mixture of
AD-M and IF demonstrated TNF production
restoration until the initial level (Fig. 1). Indivi-
duals of the third group (IF injection only)
showed a significant LPS-induced TNF produc-
tion increase (p < 0.025 in Fisher’s exact test).
The increase of spontaneous TNF production
was also observed in volunteers of the second
group (AD-M + IF) 4 weeks after vaccination
(p < 0.025 in Fisher’s exact test).
Serum levels of TNF were markedly increased
in four out of five individuals who received
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Table 1. TNF and IL-6 production levels before vaccination
Group Subject TNF (pg/ml) IL-6 (IU/ml)
no. no.
Without With LPS Without With LPS
LPS LPS
67 80 956 1687
(AD-M) 2 305 230 1242 1357
3 1017 1185 1012 800
4 817 3734 1197 1707
5 1187 1320 1020 750
II 6 131 591 1621 4073
(AD-M + IF) 7 136 587 1455 2971
8 15 20 465 1405
9 301 1529 1362 2138
10 30 62 922 2169
11 24 83 173 261
III 12 139 687 1327 2645
(IF) 13 780 1972 1072 2130
14 661 1128 380 1337
15 458 990 853 515
16 157 317 243 320
17 76 166 807 473
AD-M only as a comparison with initial levels.
No changes in serum levels of TNF have been
demonstrated in both AD-M with IF and IF only
injected subjects (Fig. 2).
Changes in IL-6 production
The IL-6 production levels before vaccination
are shown in Table 1. Evident stimulation of IL-
6 production (both spontaneous and LPS-
induced) at the 14th day after AD-M application
has been observed. No significant differences
with an initial IL-6 production were obtained
for individuals injected with mixture of AD-M
and IF or with IF only (Fig. 3).
In general, the serum level of IL-6 in vacci-
nated volunteers receiving IF was lower than in
individuals injected with AD-M only (Fig. 4).
Antitoxic antibody titre
High antitoxic antibody initial titres were shown
in five volunteers. Serum antibody levels lower
than the protective titre (1:40) have been
demonstrated in the others. The results indicate
that systemic antibody responses to diphtheria
toxoid vaccination were similar in both groups
of volunteers, with and without IF pretreat-
ment. However, the dynamics of antibody for-
mation were different in the groups (Fig. 5).
Thus, in the control group the velocity of
antibody accumulation and maximum antibody
titres in the sera were higher than in the group
pretreated with IE But 120 days after immuniza-
tion serum antigen-specific antibody titres in IF-
pretreated individuals did not differ from those
in the controls.
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FIG. 1. The effect of AD-M, AD-M + IF, and IF only on in vitro TNF production by PBMNCs. PBMNCs obtained from donors of
different groups were incubated for 2 h without (panel A) or with (panel B) LPS. The supernatants were collected and TNF
activity was quantified as described in Materials and Methods. *p < 0.05 compared with control value; **p 0.021 compared
with suppressed TNF level at the 7th day (Wilcoxon-Mann-Whitney’s U criterion). ***The use of Fisher’s exact test led us to
reject the hypothesis of random stimulation of TNF production p < 0.025).
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FIG. 2. The effect of AD-M, AD-M + IF, and IF only on serum TNF levels. The average values of TNF levels in the sera of
different individuals are presented. *p < 0.05 compared with respective control (Wilcoxon-Mann-Whitney’s U criterion).
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FIG. 3. The effect of AD-M, AD-M + IF, and IF only on in vitro IL-6 production by PBMNCs. PBMNCs obtained from donors of
different groups were incubated for 14 h without (panel A) or with (panel B) LPS. The supernatants were collected and IL-6
activity was quantified as described in Materials and Methods. *p < 0.05 compared with control value (Wilcoxon-Mann-
Whitney’s U criterion).
Discussion
Our data show that visible changes in the
proinflammatory cytokine system are detectable
after a single application of diphtheria toxoid in
low dose. The vaccination resulted in changes
of TNF and IL-6 production by PBMNCs. Thus,
TNF release was suppressed and IL-6 produc-
tion was stimulated. Similar antagonistic produc-
tion of TNF to production of IL-6 has been
observed in the sera of patients with acute
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cerebral ischaemia9 and during the course of
meningococcal infections.
1 It is well known
that TNF and IL-6 play different roles in the
immune response mechanisms. It was shown,
for example, that IL-6 can induce the produc-
tion of TNF and IL-1 antagonists.
1
Despite the TNF production being sup-
pressed, serum levels of the cytokine were
markedly increased over a period of 3 weeks
after vaccination. This contradiction may beEffect ofdiphtheria toxoid vaccination on TNF and IL-6production
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FIG. 4. The effect of AD-M, AD-M + IF, and IF only on serum
IL-6 levels. The average values of IL-6 levels in the sera of
different individuals are presented. *p< 0.05 compared
with respective control (Wilcoxon-Mann-Whitney’s U cri-
terion).
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FIG. 5. Time course of serum antitoxic antibody responses.
*p < 0.05 vs antibody titres after AD-M application without
IF (Student’s t-test).
explained by some peculiarities of our experi-
mental model. With the supernatant levels of
TNF measured 2 h after PBMNC isolation, only
the cytokine release from cellular depots has
been observed. In view of this fact the high
levels of serum TNF may correlate with cellular
depot depletion.
Our results also demonstrate that the
pharmacological correction of postvaccinal cy-
tokine production disturbances is quite possi-
ble. Both the stimulation of the suppressed TNF
production and inhibition of the elevated IL-6
release have been shown. Normalization of the
serum TNF level in IF-treated and vaccinated
subjects has been also demonstrated. It appears
that IF can act in a dualistic manner on
inflammatory cytokine production, the elevated
production is suppressed and the low one is
stimulated. A similar effect of IF has been
shown in septic patients.
6 On the other hand, a
single injection of IF delays the antigen-specific
antibody growth, although the protective titres
of antitoxic antibodies has been revealed in all
vaccinated subjects.
In prospect these data may be useful for the
prevention of postvaccinal complications in
children with neuro- and/or immunopathology
which can demonstrate inadequate response to
elevated levels of proinflammatory cytokines in
the blood.
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